• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Amplimmune

edit

Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune’s scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body’s immune system with the aim of bettering the lives of patients suffering from aberrant immunological conditions.

Recent Milestones

edit

• 
  Amplimmune received $20M in Series A funding. (1/1/06)
  Posted 4/21/10 at 8:01pm
• 
  Amplimmune added Sol Langermann as Sr VP and Chief Scientific Officer.
  Posted 1/11/13 at 8:59pm
• 
  Amplimmune added Michael Richman as President & Chief Executive Officer.
  Posted 1/11/13 at 8:59pm
• 
  Amplimmune added Gary Fanger as Sr VP and Chief Operating Officer.
  Posted 1/11/13 at 8:59pm

Videos

Screenshots

edit

Above: Amplimmune
Uploaded: 4/22/10

Sources

1. EDGAR [edit]